Abstract
Eosinophilic pneumonia (EP) often requires long-term steroid treatment, which has adverse effects. We report the case of an 83-year-old male with minimal-change nephrotic syndrome, refractory asthma and steroid-induced diabetes who developed a severe steroid-dependent EP relapse during steroid tapering. Considering his age, comorbidities and steroid dependency, treatment with benralizumab, an anti-interleukin-5 receptor antibody, was initiated. Benralizumab rapidly depleted eosinophils, leading to significant clinical and radiological improvements, allowing successful sustained tapering of prednisolone to 5 mg daily, and improving diabetes control without EP relapse. Benralizumab provides effective steroid-sparing therapy for steroid-dependent EP, particularly in complex patients.